3Qian Q, Harris PC, Torres VE. Treatment prospects for autosomal-dominant polycystic kidney disease[J]. Kidney Int,2001,59(6):2005-2022. 被引量：1
4Mostov KE. mTOR is out of control in polycystic kidneydisease [J]. Proc Natl Acad Sci U S A,2006,103 (14): 5247-5248. 被引量：1
5Leuenroth SJ, Crews CM. Targeting cyst initiation in ADPKD[J]. J Am Soc Nephrol,2009,20(1):l-3. 被引量：1
6Lieberthal W, Levine JS. The role of the mammalian tar- get of rapamycin (mTOR) in renal disease [J]. J Am Soc Nephrol,2009,20(12):2493-2502. 被引量：1
7Walz G. Therapeutic approaches in autosomal dominant polycystic kidney disease (ADPKD): is there light at the end of the tunnel? [J]. Nephrol Dial Transplant,2006,21 (7):1752-1757. 被引量：1
8Shillingford JM, Piontek KB, Germino GG, et al. Ra- pamycin ameliorates PKD resulting from conditional inactivation of Pkdl [J]. J Am Soc Nephrol,2010,21 (3): 489-497. 被引量：1
9Serra AL, Poster D, Kistler AD, et al. Sirolimus and kid- ney growth in autosomal dominant polycystic kidney dis- ease[J]. N Engl J Med,2010,363(9):820-829. 被引量：1
10Walz G, Budde K, Mannaa M, et al. Everolimus in pa- tients with autosomal dominant polycystic kidney disease [J]. N Engl J Med,2010,363(9):830-840. 被引量：1
8Leuenroth S J, Okuhara D, Shotwell JD, et al. Triptolide is a tradition- al Chinese medicine derived inhibitor of polyeystic kidney disease [ J]. Proc Natl Aead Sci USA, 2007, 104 ( 11 ) : 4389-4394. 被引量：1
